(Boursier.com) — bioMerieux does not benefit from the rebound of the market at the end of the week with a title which yields 1.1% to 88.2 euros. The value, which aligns a sixth session in a row in the red, is notably penalized by a note from Société Générale which has just downgraded the file to ‘keep’ while reducing its objective from 126 to 101 euros. The company unveiled solid half-year results on Wednesday evening and revised its annual targets slightly upwards.
©2022 Boursier.com